SLXP News Alert Salix Pharmaceuticals (SLXP) 114.92 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Salix Pharmaceuticals (SLXP) 114.92 $SLXP

DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Salix Pharmaceuticals, Ltd. Of Upcoming Deadline
Business Wire - Wed Dec 24, 4:04PM CST
Rigrodsky & Long, P.A.:
SLXP: 114.92 (-1.18)

Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 1:12PM CST
Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan 550 by May 27, 2015.
LCI: 42.29 (+1.79), SCMP: 13.75 (+0.44), SLXP: 114.92 (-1.18), BIOD: 1.36 (-0.04)

Stocks in the News: Analyst Coverage on Encana, Unisys, Salix, Cerus and Eli Lilly
PR Newswire - Wed Dec 17, 8:20AM CST
Moments ago, Realtime Equities released new analyst updates concerning several important developing situations including Encana (NYSE: ECA), Unisys (NYSE: UIS), Salix (NASDAQ: SLXP), Cerus (NASDAQ: CERS), and Eli Lilly (NYSE: LLY). Realtime Equities is the leader in realtime news, commentary and analysis - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
CERS: 6.49 (+0.29), ECA: 13.73 (-0.03), SLXP: 114.92 (-1.18), UIS: 29.77 (-0.43), LLY: 70.16 (+0.42)

Lieff Cabraser Reminds Salix Pharmaceuticals, Inc. Investors of January 6, 2015 Lead Plaintiff Deadline in Class Litigation - SLXP
Business Wire - Wed Dec 17, 7:30AM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds Salix Pharmaceuticals, Inc. ("Salix" (NasdaqGS:SLXP) investors of the January 6, 2015 deadline to move for appointment as lead plaintiff in the securities class litigation brought on behalf of investors who purchased or otherwise acquired Salix securities between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 114.92 (-1.18)

Salix rebounding from crash
at Investor's Business Daily - Tue Dec 16, 5:53PM CST
The branded prescription drugmaker said that it will clear up its inventory problems earlier than expected. Salix Pharmaceuticals (SLXP) stock plunged 34% in Nov. after its CFO resigned after wholesaler inventory levels were much higher than...
SLXP: 114.92 (-1.18)

Salix Pharmaceuticals Set to Possibly Pullback After Yesterday's Rally of 6.87%
Comtex SmarTrend(R) - Tue Dec 16, 4:26PM CST
Salix Pharmaceuticals (NASDAQ:SLXP) traded in a range yesterday that spanned from a low of $106.01 to a high of $113.10. Yesterday, the shares gained 6.9%, which took the trading range above the 3-day high of $109.56 on volume of 4.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SLXP: 114.92 (-1.18)

Talisman Energy and Salix are big market movers
AP - Tue Dec 16, 3:52PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
TLM.TO: 9.10 (-0.01), ECA: 13.73 (-0.03), TLM: 7.84 (unch), RVBD: 20.35 (+0.01), BRCM: 43.38 (-0.04), PFE: 31.42 (-0.03), SLXP: 114.92 (-1.18), EMR: 62.73 (-0.10), ARCP: 8.33 (unch), LPI: 10.61 (-0.35), ECA.TO: 15.95 (-0.07), TOUR: 12.03 (+0.30), YNDX: 17.66 (-0.32)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Salix Pharmaceuticals, Ltd. To Contact Brower Piven Before The January 6, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Dec 16, 3:31PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (Nasdaq: SLXP) securities during the period between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 6, 2015 to seek appointment as lead plaintiff.
SLXP: 114.92 (-1.18)

Salix Destocking Plan, 2-Year Guidance Soothe Street
at Investor's Business Daily - Tue Dec 16, 10:02AM CST
Fallen former IBD 50 stock Salix Pharmaceuticals (SLXP) seemed to be getting some investor credibility back Tuesday as the company said it would clear up its inventory problems earlier than expected and offered 2015 and 2016 guidance that pointed to...
SLXP: 114.92 (-1.18)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 8:10AM CST

FRO: 2.43 (-0.01), TLM: 7.84 (unch), PHMD: 1.46 (-0.03), SLXP: 114.92 (-1.18), BBEP: 7.06 (-0.23), EXAS: 27.60 (+0.39), NVGN: 2.40 (-0.09), MBT: 8.11 (+0.06), LPI: 10.61 (-0.35), CYCC: 0.69 (+0.01), GOL: 5.16 (-0.04), AUY: 3.89 (+0.15), ORAN: 17.52 (-0.04), YNDX: 17.66 (-0.32)

FDA extends Xifaxan 550 PDUFA date
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:48AM CST

SLXP: 114.92 (-1.18)

Q4 revenue is going to be light as Salix updates guidance
Seeking Alpha - at Seeking Alpha - Tue Dec 16, 7:39AM CST

SLXP: 114.92 (-1.18)

Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN(R) 550 for IBS-D Approval Timeline, and Provides Preliminary Guidance for 2015 and 2016
Business Wire - Tue Dec 16, 6:00AM CST
--Announces Extension of PDUFA Action Date for XIFAXAN(R) 550 for IBS-D to May 27
SLXP: 114.92 (-1.18)

SECURITIES ALERT: Rosen Law Firm Reminds Salix Pharmaceuticals, Ltd. Shareholders of Important Deadline in Class Action -- SLXP
GlobeNewswire - Thu Dec 11, 4:50PM CST
The Rosen Law Firm reminds purchasers of the common stock of Salix Pharmaceuticals, Ltd. (Nasdaq:SLXP) between November 8, 2013, and November 6, 2014, of the important January 6, 2015 lead plaintiff deadline in the class action.
SLXP: 114.92 (-1.18)

Can Salix Pharmaceuticals (SLXP) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 7:58AM CST
The positive earnings estimate revisions suggest that analysts are becoming more optimistic on SLXP’s earnings for the coming quarter and year
SLXP: 114.92 (-1.18)

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update
M2 - Thu Dec 11, 6:45AM CST
Research and Markets (http://www.researchandmarkets.com/research/tckqjm/pharmapoint) has announced the addition of the "PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Simponi and Entyvio, which will favor the increased uptake of biologics in the US, 5EU, Japan, and Canada. Although the number of UC prevalent cases is plateauing in the West, globally, the number of cases is rising, a phenomenon that will contribute to market growth over the next decade. Another event affecting the market is the launch of biosimilars, given the patent expiry of the UC blockbusters, Remicade and Humira, in the US in 2018 and 2016, respectively. However, the lack of an established regulatory path for biosimilars in the US presages the slow uptake of these products in this market, which could limit their availability, and consequently, inhibit the growth of the UC market. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Overall, major barriers to the growth of the UC market include - Remicade and Humira losing patent protection in the mid-forecast - Austerity measures favoring generic prescribing - Biosimilars are predicted to face low uptake due to the lack of regulatory guidelines in some markets, such as the US Key Findings - The UC market has predominantly been driven by two TNF blockers, namely J&J's Remicade and AbbVie's Humira. Although these TNF blockers have monopolized the UC market for almost a decade, the balance is about to be tipped, with Takeda's Entyvio and J&J's Simponi launch in 2014, stealing market share from Humira and Remicade. - Remicade and Humira will also be hit by their respective loss of patent protection in 2018 (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe has already approved a biosimilar to Remicade, Celltrion's Remsima, which will be marketed by Hospira under the brand name Inflectra in the EU. Due to lack of regulatory guidelines and the current debate about indication extrapolation for biosimilars based on a clinical trial in one indication, initial biosimilar uptake will be low, but by the end of the forecast period, in 2022 infliximab, adalimumab and golimumab biosimilars are forecast to become an established part of the UC market. - During the coming decade, Europe is expecting the approval and launch of a UC colectomy rescue therapy, InDex Pharmaceuticals' Kappaproct. Kappaproct is targeting a small patient population group, but due to the involvement of key gastroenterologists in the development of this therapy, it will likely be welcomed for use in this new treatment setting, which has never been addressed before by a pharmaceutical product. In addition, Pfizer's Xeljanz is expected to face low uptake post its estimated launch in 2017, owing to the controversy surrounding its rejection by the EMA for its primary indication, rheumatoid arthritis. Companies Mentioned - Johnson & Johnson - AbbVie - Takeda Pharmaceuticals - Roche - Warner Chilcott - Salix Pharmaceuticals/Santarus - Shire Pharmaceuticals - Ferring Pharmaceuticals - Pfizer - InDeX Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/tc...harmapoint
JNJ: 104.59 (+0.31), SHPG: 209.29 (+0.07), SLXP: 114.92 (-1.18)

Lieff Cabraser Reminds Salix Pharmaceuticals, Inc. Investors of Upcoming Deadline in Class Action Litigation - SLXP
Business Wire - Wed Dec 10, 6:48PM CST
The law firm of Lieff Cabraser Heimann & Bernstein, LLP reminds investors of the January 6, 2015 deadline to move for appointment as lead plaintiff in the securities class action litigation brought on behalf of investors who purchased or otherwise acquired the securities of Salix Pharmaceuticals, Inc. ("Salix" (NasdaqGS: SLXP) between November 7, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 114.92 (-1.18)

Ironwood Pharmaceuticals Advances IW-9179 to Phase IIa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 2:30PM CST
Ironwood Pharmaceuticals, Inc. (IRWD) started dosing patients in a phase IIa study on IW-9179 for the relief from symptoms associated with diabetic gastroparesis.
LCI: 42.29 (+1.79), ACT: 254.20 (-1.68), IRWD: 14.57 (+0.25), SLXP: 114.92 (-1.18)

SLXP SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Salix Pharmaceuticals, Ltd. and Its Board of Directors and a Lead Plaintiff Deadline of January 6, 2015
Business Wire - Tue Dec 09, 11:01AM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased Salix Pharmaceuticals, Ltd. ("Salix" or the "Company" (NasdaqGS:SLXP) securities between November 8, 2013 and November 6, 2014.
SLXP: 114.92 (-1.18)

Morgan & Morgan Reminds Investors That a Class Action Lawsuit Has Been Filed Against Salix Pharmaceuticals Ltd. and of the Lead Plaintiff Deadline of January 6, 2015 -- SLXP
GlobeNewswire - Tue Dec 09, 9:39AM CST
Morgan & Morgan reminds investors that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Salix Pharmaceuticals Ltd. ("Salix" or the "Company" (Nasdaq:SLXP) securities between November 8, 2013 and November 6, 2014, inclusive (the "Class Period" .
SLXP: 114.92 (-1.18)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 54

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Mars Sets $2 Billion Debt Tender With Kellanova Notes

Updated Category News Views 124

A two-billion-dollar vacuum cleaner just switched on inside Mars’s debt stack, and the timing is anything but casual. On November 20, Mars fixed the pricing for cash tender offers spanning selected Mars and Kellanova senior notes, with holders facing a 5:00 p.m. New York deadline that same day. This is the kind of filing that looks like bond-market plumbing until you...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sidus Gains Argotec Order, but Investors Need the Math

Updated Category News Views 149

A Real Customer Signal, Minus the Revenue Figure An updated image is the least interesting detail in this release. Sidus Space has landed a purchase order from Argotec Group to manufacture cable assemblies for the HAWK satellite platform, with delivery expected in the first quarter of 2027. That is a legitimate operational win for NASDAQ:SIDU. It brings in a new...

Continue Reading
Saturn and Tileward Put GPU Memory Back to Work Now

Updated Category News Views 49

GPU memory is the tollbooth nobody notices until the whole AI highway backs up. Saturn Cloud’s new partnership with Tileward goes straight at that constraint: use compressed open-model weights, free memory on hardware already installed, and turn that reclaimed capacity into more tokens that an operator can actually sell. It is not glamorous. It may be one of the more...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 78

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 73

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Tampa General's Food Bet Earns a 2026 Innovation Award

Updated Category News Views 41

Hospital meals have long been the punchline nobody bothered to fix, which is why Tampa General Hospital's latest recognition deserves a closer look. The not-for-profit academic health system was named the 2026 Inno Pick by the Tampa Bay Business Journal for its Food as Medicine initiative, its fifth straight year landing among the publication's Inno Award honorees. Awards...

Continue Reading

Top 5 Most Recently Viewed Articles

Ivalua Celebrates Winning Multiple Best Company Awards

Updated Category News Views 104

Ivalua Celebrates Its Recognition with Multiple Best Company Awards Ivalua, a leader in spend management solutions, is excited to share its recent achievements at the Comparably Awards. The company received accolades for Happiest Employees, Best Company Perks & Benefits, and Best Company Work-Life Balance. This recognition underscores Ivalua's commitment to creating an...

Continue Reading
Global Peace Index Reveals Increasing Conflict Trends

Updated Category News Views 371

The 2025 Global Peace Index: A Rising Tide of Conflict The recently released 2025 Global Peace Index (GPI) by the Institute for Economics & Peace (IEP) highlights a troubling trend of declining global peacefulness. The report indicates that we are witnessing a significant change in the global landscape, pointing to a stark reality where conditions leading to conflict are...

Continue Reading
Innovative Device Revolutionizes Painting Techniques and Efficiency

Updated Category News Views 227

Transformative Invention for Painters In the world of painting, efficiency and effectiveness are paramount. Inventors continually seek ways to improve the tools that workers use. One new device, the LOCK & ROLL, aims to enhance the painting experience significantly. Introduction to the LOCK & ROLL This innovative invention is designed to securely anchor paint rollers atop...

Continue Reading
Norfolk Southern's Leadership Crisis: Alan Shaw's Upcoming Exit

Updated Category News Views 130

Norfolk Southern at a Crossroads as Alan Shaw Faces Scrutiny Norfolk Southern Corporation is navigating a tense moment. Chief Executive Alan Shaw is under investigation for alleged ethical violations, including a purported relationship with a company employee. The review has raised questions about leadership, culture, and what accountability should look like at one of the...

Continue Reading
West USA Realty Partners with Zillow to Enhance Listings

Updated Category News Views 235

West USA Realty Embraces Transparency with Zillow West USA Realty, a leading name in the real estate industry, is taking a bold step by aligning with Zillow's standards for consumer access to property listings. This partnership reflects a mutual commitment to transparency and aims to enhance the experience for home buyers and sellers alike. Commitment to Consumers As the...

Continue Reading